S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   183.41 (+1.36%)
MSFT   336.02 (+0.18%)
META   272.09 (-0.19%)
GOOGL   125.06 (+0.31%)
AMZN   124.26 (+0.01%)
TSLA   219.06 (+2.38%)
NVDA   393.30 (+0.01%)
NIO   7.69 (+1.72%)
BABA   84.00 (-0.32%)
AMD   117.25 (-0.52%)
T   15.32 (+0.72%)
F   12.64 (+2.02%)
MU   68.75 (-0.61%)
CGC   0.82 (-0.32%)
GE   105.34 (-0.43%)
DIS   90.42 (-0.39%)
AMC   4.63 (+1.76%)
PFE   38.51 (+0.39%)
PYPL   64.35 (+0.61%)
NFLX   402.81 (+0.58%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   183.41 (+1.36%)
MSFT   336.02 (+0.18%)
META   272.09 (-0.19%)
GOOGL   125.06 (+0.31%)
AMZN   124.26 (+0.01%)
TSLA   219.06 (+2.38%)
NVDA   393.30 (+0.01%)
NIO   7.69 (+1.72%)
BABA   84.00 (-0.32%)
AMD   117.25 (-0.52%)
T   15.32 (+0.72%)
F   12.64 (+2.02%)
MU   68.75 (-0.61%)
CGC   0.82 (-0.32%)
GE   105.34 (-0.43%)
DIS   90.42 (-0.39%)
AMC   4.63 (+1.76%)
PFE   38.51 (+0.39%)
PYPL   64.35 (+0.61%)
NFLX   402.81 (+0.58%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   183.41 (+1.36%)
MSFT   336.02 (+0.18%)
META   272.09 (-0.19%)
GOOGL   125.06 (+0.31%)
AMZN   124.26 (+0.01%)
TSLA   219.06 (+2.38%)
NVDA   393.30 (+0.01%)
NIO   7.69 (+1.72%)
BABA   84.00 (-0.32%)
AMD   117.25 (-0.52%)
T   15.32 (+0.72%)
F   12.64 (+2.02%)
MU   68.75 (-0.61%)
CGC   0.82 (-0.32%)
GE   105.34 (-0.43%)
DIS   90.42 (-0.39%)
AMC   4.63 (+1.76%)
PFE   38.51 (+0.39%)
PYPL   64.35 (+0.61%)
NFLX   402.81 (+0.58%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   183.41 (+1.36%)
MSFT   336.02 (+0.18%)
META   272.09 (-0.19%)
GOOGL   125.06 (+0.31%)
AMZN   124.26 (+0.01%)
TSLA   219.06 (+2.38%)
NVDA   393.30 (+0.01%)
NIO   7.69 (+1.72%)
BABA   84.00 (-0.32%)
AMD   117.25 (-0.52%)
T   15.32 (+0.72%)
F   12.64 (+2.02%)
MU   68.75 (-0.61%)
CGC   0.82 (-0.32%)
GE   105.34 (-0.43%)
DIS   90.42 (-0.39%)
AMC   4.63 (+1.76%)
PFE   38.51 (+0.39%)
PYPL   64.35 (+0.61%)
NFLX   402.81 (+0.58%)

Ventyx Biosciences (VTYX) Stock Forecast, Price & News

$33.63
-0.37 (-1.09%)
(As of 09:39 AM ET)
Compare
Today's Range
$33.63
$34.94
50-Day Range
$28.53
$39.55
52-Week Range
$11.07
$47.25
Volume
4,757 shs
Average Volume
774,168 shs
Market Capitalization
$1.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.40

Ventyx Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
64.7% Upside
$55.40 Price Target
Short Interest
Bearish
19.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of Ventyx Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$15.80 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.76) to ($3.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

668th out of 980 stocks

Pharmaceutical Preparations Industry

333rd out of 485 stocks


VTYX stock logo

About Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Stock News Headlines

New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Ventyx Biosciences (VTYX) Gets a Buy from LifeSci Capital
The Latest Analyst Ratings for Ventyx Biosciences
Q1 2023 Ventyx Biosciences Inc Earnings Call
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Ventyx Biosciences (VTYX) Receives a Buy from Goldman Sachs
See More Headlines

VTYX Price History

VTYX Company Calendar

Last Earnings
3/23/2023
Today
6/04/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTYX
Fax
N/A
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.40
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+62.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-108,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.37 per share

Miscellaneous

Free Float
44,118,000
Market Cap
$1.98 billion
Optionable
Not Optionable
Beta
-0.36

Key Executives

  • Dr. Sheila K. Gujrathi M.D. (Age 53)
    Exec. Chair
    Comp: $81.14k
  • Dr. Raju S. Mohan Ph.D. (Age 65)
    Founder, CEO & Director
    Comp: $783.73k
  • Dr. John M. Nuss Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $5.57M
  • Mr. Christopher W. Krueger J.D. (Age 55)
    MBA, Chief Bus. Officer
    Comp: $568.14k
  • Prof. William J. Sandborn M.D.
    Ph.D., Pres & Chief Medical Officer
  • Dr. Martin Douglas Auster M.D. (Age 48)
    Chief Financial Officer













VTYX Stock - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VTYX shares.
View VTYX analyst ratings
or view top-rated stocks.

What is Ventyx Biosciences' stock price forecast for 2023?

8 analysts have issued twelve-month price objectives for Ventyx Biosciences' shares. Their VTYX share price forecasts range from $35.00 to $77.00. On average, they anticipate the company's stock price to reach $55.40 in the next year. This suggests a possible upside of 62.9% from the stock's current price.
View analysts price targets for VTYX
or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2023?

Ventyx Biosciences' stock was trading at $32.79 on January 1st, 2023. Since then, VTYX stock has increased by 3.7% and is now trading at $34.00.
View the best growth stocks for 2023 here
.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VTYX earnings forecast
.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) posted its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.03.

When did Ventyx Biosciences IPO?

(VTYX) raised $152 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share.

What is Ventyx Biosciences' stock symbol?

Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX."

Who are Ventyx Biosciences' major shareholders?

Ventyx Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (13.35%), Price T Rowe Associates Inc. MD (4.71%), BlackRock Inc. (3.60%), RTW Investments LP (2.44%), Wellington Management Group LLP (1.53%) and Pictet Asset Management SA (1.31%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends
.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ventyx Biosciences' stock price today?

One share of VTYX stock can currently be purchased for approximately $34.00.

How much money does Ventyx Biosciences make?

Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $1.98 billion. The company earns $-108,430,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

How can I contact Ventyx Biosciences?

The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com.

This page (NASDAQ:VTYX) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -